Blueprint Medicines Sustainability Profile
Blueprint Medicines Corporation, headquartered in the United States, is a pioneering biotechnology company focused on targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy. Founded in 2008, the company has achieved significant milestones, including the development of innovative treatments that address unmet medical needs. With a strong emphasis on precision medicine, Blueprint Medicines offers a portfolio of unique products, including targeted therapies that inhibit specific genetic mutations. This approach not only enhances treatment efficacy but also minimises side effects, setting the company apart in the competitive biotech landscape. Recognised for its commitment to advancing patient care, Blueprint Medicines has established a prominent market position, driven by its robust pipeline and strategic collaborations. The company continues to lead the way in transforming the treatment landscape for patients with complex diseases.
DitchCarbon Score
How does Blueprint Medicines's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Blueprint Medicines's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Blueprint Medicines, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Sanofi, which influences its climate commitments and initiatives. As a current subsidiary of Sanofi, Blueprint Medicines inherits climate-related targets and initiatives from its parent company. Sanofi has set ambitious science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These targets are cascaded down to Blueprint Medicines, reflecting a commitment to sustainability and climate action. While specific reduction targets for Blueprint Medicines are not detailed, the overarching initiatives from Sanofi include commitments to renewable energy and emissions reduction strategies. This includes participation in the RE100 initiative, which aims for 100% renewable electricity, and the CDP reporting framework, which encourages transparency in environmental impact. In summary, while Blueprint Medicines does not provide specific emissions data, it aligns with the climate commitments and reduction strategies established by its parent company, Sanofi, demonstrating a commitment to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Blueprint Medicines's Industry?
How Carbon Intensive is Blueprint Medicines's Location?
Blueprint Medicines's Scope 3 Categories Breakdown
Blueprint Medicines's Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Blueprint Medicines's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Blueprint Medicines has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
